News
Public · Published
Mark Cuban Says Public Companies Found They Were 'Ripped Off' On Healthcare But Won't Say So On Earnings Calls
Mark Cuban said some public companies audited their health plans, found they were overcharged by insurers including UnitedHealth Group, CVS Health and Cigna, but refused to disclose the findings on quarterly earnings calls because they still do business with those insurers.
Published:
Updated:
What happened
Mark Cuban said some public companies audited their health plans, found they were overcharged by insurers including UnitedHealth Group, CVS Health and Cigna, but refused to disclose the findings on quarterly earnings calls because they still do business with those insurers.
Confirmed
Global impact / market context
If companies are paying more than needed for employee health benefits, that extra cost reduces profit and cash available for other uses. Investors may not see this cost clearly because firms avoid discussing it publicly, which means reported earnings can look stronger than the underlying economics suggest.
Analyst inference
The article ties the issue to insurer and pharmacy benefit manager practices, which means middlemen who negotiate drug and benefit contracts. Cuban supports the Break Up Big Medicine Act, a proposal requiring insurers to divest pharmacy benefit managers and provider assets, so regulation could reshape how these contracts are priced and disclosed.
Analyst inference
What to watch
- Cuban cited a Dallas pharmacy benefit manager contract topping 1,300 pages, showing how long and complex these agreements are, which makes it hard for company staff to catch every clause and charge. Confirmed
- The Break Up Big Medicine Act would require insurers to divest pharmacy benefit managers and provider assets, so watch whether this proposal advances, since it could change insurer business structures and contract negotiations. Proposed
- Watch whether any named public company discloses health-plan audit findings on an earnings call, because such disclosure could pressure other firms to review insurer contracts and could shift investor views on insurer revenue. Analyst inference